 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Myriad Data Shows Reduced Rate of Variants of Unknown Significance for BRACAnalysis, Colaris Tests
June 27, 2012
Myriad Data Shows Reduced Rate of Variants of Unknown Significance for BRACAnalysis, Colaris Tests
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GenomeWeb Feature: Regardless of Gene Patent Challenges, Myriad Faces Shifting Competitive Landscape
April 17, 2013 / Pharmacogenomics Reporter - Myriad Expects BRACAnalysis to Remain Best Seller in 'Post-Patent' Era
February 6, 2013 / Pharmacogenomics Reporter - Continuing Revenue Growth in Third Quarter, Myriad Keeps Focus on Diversifying MDx Product Portfolio
May 8, 2013 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - Hearing on Second-Opinion Genetic Testing Highlights Risks of Athena's Exclusive Licensing Practices
January 16, 2013 / Pharmacogenomics Reporter